• Mike Adelstein
  • March 23, 2021

Microneedles for vaccine delivery

Microneedles for vaccine delivery

Microneedle-based drug delivery has the potential to be a transformative technology for the delivery of biologics and vaccines. It may provide enhanced therapeutic profiles for therapeutics and vaccines. It allows for the administration of lower levels of drugs to achieve the same therapeutic endpoints. Additionally, microneedles provide an alternative to traditional hypodermic needles. This industry provides a means to overcome one of the biggest barriers to patient compliance and safety for the treatment of chronic diseases and routine vaccination. The variation in the microneedle types could also prove useful in controlling the kinetics of vaccine release. The importance of overcoming stratum corneum barrier is central to the efficient Microneedle-mediate transdermal and intradermal delivery. 1,2

Several new transdermal products mediated by microneedle methods have already been marketed and a few others reach their late-stage development. According to “The Microneedles for Transdermal and Intradermal Drug Delivery, 2014-2030” report, more than 70% of the products in development are patches incorporating solid or dissolvable needles, the rest are hollow microneedle arrays that employ the use of a syringe. However, microneedle technologies have not reached their full maturity, yet due to a lack of cost-effective manufacturing technologies. With several new microneedle-based therapeutic product launches by the end of this decade, the report concludes that the overall market for microneedle-based delivery devices will reach annual sales of 485 million units by 2030. https://www.medicaldesignandoutsourcing.com/microneedle-patches-enable-superior-drug-delivery

The images shown here are microneedle molds (diameters of 250 µm to 1 mm) prepared using Potomac’s precision laser etching technologies.

References:

  1. Tuan-Mahmood, T.-M. et al. Microneedles for intradermal and transdermal drug delivery. Eur. J. Pharm. Sci. 50, 623–37 (2013).
  2. Rouphael, N. G. et al. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet 390, 649–658 (2017).

 

 

Other Posts

Article Review: What We Talk about when We Talk about Microfluidics.

Based on an article by Albert Folch in “The Conversation “ Nanotechnology can protect us. The Covid-19 test was created in response to a world- wide emergency. The test is based on a micro fluidic system. Microfluidic systems are based on the physical principle of laminar flow. Laminar flow determines that small amounts of fluid flow…

  • Sandy Matatquin
  • September 13, 2021

Delivering Parts at the Speed of Light for Protein Analysis Research at Arizona State University

The old days of university research labs having all the time in the world to complete experiments are gone. Like for everything else in the 21st century, time is of the essence for university researchers to compete in the latest grant rounds or to fulfill requirements for corporate partners. Speed is the name of the game…

  • Mike Adelstein
  • July 14, 2021

Potomac Automates Quality Control Inspection via In-house Innovative Software Development

Today, speed is the name of the game.  But speed without accuracy in all its forms defeats the purpose of fast delivery.  At Potomac, we provide some of the quickest turnaround in manufacturing for medical device, microfluidic, biotech, consumer product and microelectronics customers also with the highest level of quality. Meeting customer specifications is especially…

  • Potomac Photonics
  • February 8, 2021